Matching-adjusted indirect comparison (MAIC) is a statistical technique that simulates a direct comparison of two therapies (4, 5) by matching individual patient data (IPD) from one trial to published aggregate data from another trial (6, 7).
The matching-adjusted indirect comparison and associated report completed by MAPI Group were funded by Novartis Pharma AG.
Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
A Matching-adjusted Indirect Comparison of Bortezomib-Thalidomide-Dexamethasone and Daratumumab Plus Bortezomib-Thalidomide-Dexamethasone Versus Bortezomib-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - Poster presentation, Saturday, September 14, 12:30 PM - 2:00 PM EDT
A Matching-adjusted Indirect Comparison of Daratumumab-Bortezomib-Thalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - Poster presentation, Saturday, September 14, 12:30 PM - 2:00 PM EDT
Which of the following statements most accurately describes the results of a matching-adjusted indirect comparison
between data for two biologic therapies in psoriatic arthritis (PsA)?
In addition, analyses, using Matching-Adjusted Indirect Comparison
(MAIC) presented at ACR show Cosentyx may improve the signs and symptoms of AS and PsA more than Humira (adalimumab).
Matching-adjusted indirect comparison (MAIC) is an analytical method for an indirect comparison that uses a form of propensity score weighting of individual patient data (IPD) to match patients from one trial with those from another for baseline characteristics, especially those that may influence treatment response (8, 9).
Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: a matching-adjusted indirect comparison. Ann Rheum Dis 2016; 75: 98-9.
A matching-adjusted indirect comparison
(MAIC), adjusting for differences in patient baseline characteristics, was performed to simulate a head-to-head comparison between data from phase III trials of secukinumab and of adalimumab 40 mg every 2 weeks.
Erder et al., "Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research," Value in Health, vol.
Yu et al., "Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept," PharmacoEconomics, vol.